Imunon, Inc. (IMNN)
NASDAQ: IMNN · Real-Time Price · USD
1.040
-0.030 (-2.80%)
At close: Oct 14, 2026, 4:00 PM EDT
1.030
-0.010 (-0.96%)
After-hours: Oct 14, 2026, 7:36 PM EDT
Imunon Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
20
Market Cap
5.84M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 500.00K | - | - |
| Dec 31, 2021 | 500.00K | - | - |
| Dec 31, 2020 | 500.00K | - | - |
| Dec 31, 2019 | 500.00K | - | - |
| Dec 31, 2018 | 500.00K | - | - |
| Dec 31, 2017 | 500.00K | - | - |
| Dec 31, 2016 | 500.00K | - | - |
| Dec 31, 2015 | 500.00K | - | - |
| Dec 31, 2014 | 500.00K | - | - |
| Dec 31, 2013 | 500.00K | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | 2.00M | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | 2.50M | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Traws Pharma | 2.73M |
| Evogene | 1.66M |
| Can-Fite BioPharma | 405.00K |
| AIM ImmunoTech | 95.00K |
| Creative Medical Technology Holdings | 3.00K |
IMNN News
- 6 days ago - IMUNON to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 15 days ago - IMUNON Converts $1.2 Million of Debt-to-Equity - GlobeNewsWire
- 20 days ago - Imunon presents update on its IMNN-001 development program - TheFly
- 20 days ago - IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan - GlobeNewsWire
- 21 days ago - Imunon Transcript: R&D Day 2026 - Transcripts
- 21 days ago - Imunon Slides: FY 2026 - Filings
- 22 days ago - Imunon announces IDMC recommends continued Phase 2 development of IMNN-001 - TheFly
- 22 days ago - IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review - GlobeNewsWire